| scholarly article | Q13442814 |
| P50 | author | Bjarne Bogen | Q64441612 |
| P2093 | author name string | Tohru Izumi | |
| Yusuke Furukawa | |||
| Daisuke Koyama | |||
| Jiro Kikuchi | |||
| Peter O Hofgaard | |||
| Taeko Wada | |||
| P2860 | cites work | Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells | Q24293124 |
| Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2 | Q24302263 | ||
| Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas | Q24339074 | ||
| A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease | Q27329429 | ||
| Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes | Q27851571 | ||
| Histone methylation: a dynamic mark in health, disease and inheritance | Q28263573 | ||
| Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3 | Q28276951 | ||
| A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations | Q29614275 | ||
| Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders | Q29614510 | ||
| Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma | Q29616862 | ||
| Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia | Q33732419 | ||
| Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus | Q33826685 | ||
| Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model | Q33840195 | ||
| Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas | Q33860585 | ||
| Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells | Q33948015 | ||
| Regulation and Role of EZH2 in Cancer | Q34043370 | ||
| Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation | Q34133622 | ||
| Non-invasive imaging provides spatiotemporal information on disease progression and response to therapy in a murine model of multiple myeloma | Q34540657 | ||
| The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. | Q34568855 | ||
| CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells | Q34789033 | ||
| Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia | Q35742745 | ||
| Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress | Q35750893 | ||
| Total kinetic analysis reveals how combinatorial methylation patterns are established on lysines 27 and 36 of histone H3 | Q36187444 | ||
| Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. | Q36333522 | ||
| The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. | Q36384699 | ||
| IRF4 addiction in multiple myeloma | Q36891060 | ||
| PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma | Q37016007 | ||
| The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases | Q37132187 | ||
| Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. | Q37207049 | ||
| Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells | Q37260512 | ||
| Markers of stemness in equine mesenchymal stem cells: a plea for uniformity | Q37825109 | ||
| Novel therapies in MM: from the aspect of preclinical studies | Q37924637 | ||
| Histone lysine methylation dynamics: establishment, regulation, and biological impact | Q38064095 | ||
| Phosphorylation of EZH2 by CDK1 and CDK2: a possible regulatory mechanism of transmission of the H3K27me3 epigenetic mark through cell divisions | Q38448802 | ||
| Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells. | Q39007207 | ||
| Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma | Q39040982 | ||
| Romidepsin overcomes cell adhesion-mediated drug resistance in multiple myeloma cells. | Q39041783 | ||
| Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma | Q39721223 | ||
| Methylation of histone H3 lysine 27 associated with apoptosis in osteosarcoma cells induced by staurosporine | Q39824232 | ||
| MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. | Q39908262 | ||
| Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma | Q39930099 | ||
| Difference between genomic actions of estrogen versus raloxifene in human ovarian cancer cell lines | Q40025452 | ||
| Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. | Q40629582 | ||
| Rapid ex vivo expansion of human umbilical cord hematopoietic progenitors using a novel culture system | Q40952351 | ||
| Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells | Q41360812 | ||
| Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders | Q41775948 | ||
| A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia | Q42053261 | ||
| Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms | Q44452179 | ||
| Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation | Q88128182 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phosphorylation | Q242736 |
| multiple drug resistance | Q643839 | ||
| P304 | page(s) | 4375-4390 | |
| P577 | publication date | 2015-10-26 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma | |
| P478 | volume | 125 |
| Q91559728 | A lncRNA coordinates with Ezh2 to inhibit HIF-1α transcription and suppress cancer cell adaption to hypoxia |
| Q38714809 | ADP-ribosylation factor 1 (ARF1) takes part in cell proliferation and cell adhesion-mediated drug resistance (CAM-DR). |
| Q52649655 | Anthelmintic pyrvinium pamoate blocks Wnt/β-catenin and induces apoptosis in multiple myeloma cells. |
| Q49592081 | Bone marrow stromal cells enhance the survival of chronic lymphocytic leukemia cells by regulating HES-1 gene expression and H3K27me3 demethylation |
| Q59798121 | Cancer Stem Cells: Emergent Nature of Tumor Emergency |
| Q49559891 | Cell adhesion-induced phosphorylation and inactivation of EZH2 confer drug resistance to acute myeloid leukemia cells |
| Q38734339 | Dynamic Protein Interactions of the Polycomb Repressive Complex 2 during Differentiation of Pluripotent Cells |
| Q59790124 | EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies |
| Q39340502 | EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe? |
| Q55018505 | EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes. |
| Q59795355 | EZH2, HIF-1, and Their Inhibitors: An Overview on Pediatric Cancers |
| Q38895512 | Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma. |
| Q39021977 | Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation |
| Q39261435 | Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma |
| Q39137683 | Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma |
| Q90287040 | Eradication of Central Nervous System Leukemia of T-Cell Origin with a Brain-Permeable LSD1 Inhibitor |
| Q55261902 | Frequent epigenetic alterations in polycomb repressive complex 2 in osteosarcoma cell lines. |
| Q37065194 | HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer |
| Q87789752 | Hypoxia-inducible KDM3A addiction in multiple myeloma |
| Q38690278 | Inside the Cell: Integrins as New Governors of Nuclear Alterations? |
| Q49787437 | Lysine-specific demethylase 1 inhibitors prevent teratoma development from human induced pluripotent stem cells. |
| Q39185604 | Mechanisms of Resistance in Multiple Myeloma |
| Q89565340 | Molecular basis of clonal evolution in multiple myeloma |
| Q55025408 | Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance. |
| Q39035829 | Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer |
| Q39379624 | Role of epigenetics-microRNA axis in drug resistance of multiple myeloma |
| Q27853336 | Single nucleotide polymorphism in the microRNA-199a binding site of HIF1A gene is associated with pancreatic ductal adenocarcinoma risk and worse clinical outcomes |
| Q92266478 | Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7 |
| Q60960086 | The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response |
| Q58718492 | The biological significance of histone modifiers in multiple myeloma: clinical applications |
| Q28075927 | The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential |
Search more.